Welcome for PCWC BJUI supplement A global perspective from the Prostate Cancer World Congress
Efficacy and safety of abiraterone acetate in asymptomatic or mildly symptomatic chemotherapy-naïve patients with metastatic castrationresistant prostate cancer: a phase III, double-blind, randomized, placebo-controlled study conducted in China, Malaysia, Thailand and Russia : 015
Permanent interstitial low-dose-rate brachytherapy for patients with clinically localized prostate cancer in Singapore : 016
Chidambaram scrotal dressing : 017
PSA and the detection of prostate cancer in a multi-ethnic Asian setting : 022
A prospective study evaluating functional outcome of palliative transurethral resection in locally advanced and metastatic prostate cancer : 023
Prospective evaluation of the utility of %p2PSA and the Prostate Health Index (PHI), in predicting prostate cancer in initial prostate biopsies of Singaporean men, with total PSA between 4.0 and 10 ng/mL : 024
Risk of second primary cancer among prostate cancer patients in Korea: a population-based cohort stud : 026
Should we be investing in the training of laparoscopic radical prostatectomy in Australia? A cost analysis based on the Australian experience of 2,735 cases : 027
Is active surveillance safe for patients with intermediate-risk prostate cancer? : 028
Effect of serum testosterone and percent tumor volume on extraprostatic extension and biochemical recurrence after laparoscopic radical prostatect : 030
Diagnostic utility of noninvasive testing and transrectal ultrasound in prostate carcinoma : 033
Initial results of the intensitymodulated radiation therapy for localized and locally advanced prostate cancer (IMRT) : 036
Correlation and diagnostic performance of PSA level with the diagnosis, aggressiveness and bone metastasis of prostate cancer in clinical practice : 038
The role of androgen deprivation therapy in prostate cancer patients with non-metastatic disease recurrence after local curative treatment: a systematic review : 039
Bowel quality of life after prostate external beam radiation therapy in Victoria : 040
Impact and needs of prostate cancer survivors in a country with low incidence of prostate cancer : 041
Gene expression profile of recurrent prostate cancer : 043
Prostate-specific antigen bounce after intensity-modulated radiation therapy in an Asian population : 046
Prevention and management of complications during roboticassisted laparoscopic radical prostatectomy from comprehensive planning: experience of a single surgeon of 1,000 cases : 048
Predictors of prostate cancer detection at repeat biopsy in patients with previous diagnoses of atypical small acinar proliferation : 049
A cost utility analysis of prostate cancer screening and surveillance in Australia : 051
Severing neurovascular bundle at only one side adversely affects short term continence recovery after radical prostatectomy in high risk prostate cancer patients : 052
Comparison of prostate specific antigen and prostate health index in guiding the decision on transrectal ultrasound-guided prostate biopsy: an indirect cost analysis : 053
TRUS biopsy of the prostate does not result in a higher rate of urosepsis when compared to template biopsy : 058
Abiraterone acetate after docetaxel-based chemotherapy failure in Asian patients with metastatic castration-resistant prostate cancer : 059
Androgen deprivation therapy and the risk of acute myocardial infarction in Chinese men with prostate cancer : 071
Biochemical recurrence rates in active surveillance candidates and the role of improving Gleason grading : 072
Determining three prognostic group using roach formula and other prognostic factors in chinese populations with localized prostate cancer treated with intensitymodulated radiotherapy (IMRT) : 073
The reduction of infection rate using standardize peri-operative and post-operative protocol for ultrasound-guided prostate biopsy: 5 years clinical experience of 583 patients at Changhua Christian Hospital : 083
Rates and predictive factors of Gleason score upgrade in a cohort of Australian men undergoing robotic-assisted radical prostatectomy : 086
Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center : 087
Antitumor activity of taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in study COU-AA-302 for metastatic castration-resistant prostate cancer (mCRPC) : 088
The Australian laparoscopic non robotic radical prostatectomy experience - analysis of 2,943 cases : 089
Health economic modelling for treatments and services in prostate cancer care: a master model for Australia : 093
Using the clinico-genetic model for predicting lymph node invasion by genome-based biomarkers from exome array among prostate cancer patients : 098
Outcome analysis of transperitoneal versus extraperitoneal robot assisted radical prostatectomy: a singlecentre, single-surgeon experience : 099
Quality of life of patients having transperineal biopsies for the diagnosis of prostate cancer : 101
The PREVAIL trial of enzalutamide (ENZA) in men with chemotherapynaïve, metastatic castrationresistant prostate cancer (mCRPC): subgroup analysis of Asian patients : 113
Magnetic resonance imaging for prostate cancer - a review of comparative studies including template transperineal biopsy and radical prostatectomy specimens : 114
Magnetic resonance imaging for prostate cancer - a comparative study including radical prostatectomy specimens : 115
Long-term (LT) Exposure to lowdose prednisone given with or without abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients : 118
Correlation between clinical and pathological parameters in patients diagnosed with localized prostate cancer who underwent radical prostatectomy: implications on active surveillance as a form of initial management in Filipino patients : 119
Robotic-assisted laparoscopic radical prostatectomy for preoperatively suspicious prostate cancer patients - is a novel indication for robotic surgery? : 121
Patterns of surgical care of prostate cancer in New South Wales: a population-based descriptive study : 122
Lympho-vascular involvement of seminal vesicle invasion in prostatic adenocarcinoma correlates biochemical recurrence free survival in the radical prostatectomy series : 123
A retrospective analysis of South Australian and Victorian clinical registries for prostate cancer : 125
Open versus robotic-assisted radical prostatectomies in the Victorian prostate cancer registry (PCR) - analysis at 2-year follow-up : 128
Using active surveillance in biopsy proven Gleason 3 + 4 prostate cancer : 131
Transrectal USS guided prostate needle biopsy as outpatient under local anaesthesia in regional setting : 132
The utility of multiparametric MRI guided transperineal prostate biopsy in the detection of occult prostatic cancer: a single operator experience : 134
Prostate cancer and melanoma: are there shared risk factors? : 135
Concomitant salvage radical prostatectomy with partial nephrectomy in a patient with radio-resistant prostate cancer with an incidental renal mass: a case report : 136
Prostate health index and %p2PSA predict worse pathological outcomes in radical prostatectomy in Chinese men : 139
Impact of PSMA PET scan on prostate cancer management : 140
Role of pre-treatment factors in response of castrate resistant prostate cancer patients to docetaxel therapy: the indian experience : 142
Do active surveillance patients have an increased risk of TRUS sepsis? : 148
Risk determinants of prostate cancer in the NSW Cancer Lifestyle and Evaluation of Risk Study (CLEAR) : 150
The changing profile of prostate cancer in South Australia : 152
MRI invisible prostate cancer - can we discharge patients with PIRADS score 1 or 2 without a prostate biopsy? : 153
Magnetic resonance imagingultrasound fusion targeted transperineal biopsy: ‘hitting the target or the bulls eye?’ A concordance study with radical prostatectomy specimens : 154
Delays in prostate cancer treatment following diagnosis : 155
The short-term efficacy and safety of post chemotherapy abiraterone acetate with prednisone in metastatic castration-resistant prostate cancer patients in VGHTC : 158
Risk of suicide after a prostate cancer diagnosis: a populationwide study in New South Wales (NSW) Australia : 160
Satisfaction with care in men with prostate cancer : 161
Ten-year quality of life and psychological outcomes of men managed entirely with active surveillance: The NSW Prostate Cancer Care and Outcomes Study : 162
Men presenting with prostate specific antigen (PSA) levels over 100 ng/mL at the time of diagnosis : 165
Does patient obesity influence prostate motion during external beam radiation therapy? : 170
Malignant priaprism - a rare manifestation of prostate cancer : 174
Oncological and functional outcomes of laparoscopic radical prostatectomies (LRP) - findings in the Victorian Prostate Cancer Registry (PCR) : 175
Prostate cancer detection rate in Indonesian men : 177
Correlation between multiparametric MRI findings and radical prostatectomy specimens : 179
Clinical significance of focal atrophy in benign prostatic hyperplasia patients : 181
Comparison of non-index tumours found in radical prostatectomy specimens and their detection by multiparametric MRI: what are the implications for focal therapy? : 182
ASPIRE-PCa: initial findings from a prospective, global observational study of men with late-stage prostate cancer : 195
Neurovascular bundle stimulation results in rhabdosphincter contraction in a proportion of men undergoing radical prostatectomy : 196
Evaluation of detection rate of 68Ga-PSMA-ligand PET/CT for biochemical recurrence after radical prostatectomy : 197
Re-do prostatectomy after subtotal robotic assisted laparoscopic radical prostatectomy : 198
Preliminary experience on the use of Tachosil® in robot-assisted laparoscopic radical prostatectomy (RaLRP) : 200
What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from canada versus countries with lower gross domestic product : 203
Prospective comparison of the detection rate of 18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy : 205
Prospective study of pre-biopsy multiparametric magnetic resonance imaging (mpMRI) compared to transperineal template mapping biopsy (TTMB) for detection of clinically significant prostate cancer: is it accurate enough to guide selection of men for biopsy? : 206
Cardamonin inhibits signal transducer and activator of transcription 3 activation by directly binding SH2 to its domain in prostate cancer cells : 018
Depletion of L1CAM by siRNA inhibits prostatic cancer cell invasion in vitro : 029
Comparison of patient-reported quality-of-life and complications in men with prostate cancer, between two modes of administration : 031
A descriptive analysis of diagnostic and treatment characteristics of men with prostate cancer from a regional area with high mortality rates in Victoria, Australia : 032
Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer chemo-/radio-resistance in cell lines in vitro and in animal models in vivo : 034
Reactive stroma componentCOL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth : 035
Heberprovac, a therapeutic GnRH based vaccine to treat advanced prostate cancer : 037
Inhibition of ASCT2-mediated glutamine uptake blocks prostate cancer growth : 042
Multimodality imaging of a novel spontaneous prostate cancer liver metastasis model : 044
The mutational landscape of the mitochondrial genome in prostate cancer : 055
Enrichment and propagation of circulating tumour cells in men with hormone naïve metastatic prostate cancer : 062
Investigating the role of a potential angiogenic target, YKL40, for the treatment of metastatic prostate cancer : 063
Combination of LBH589 and radiotherapy overcomes radioresistance in radioresistant prostate cancer cells in vitro and animal models in vivo : 064
The ghrelin receptor antisense long non-coding RNA, GHSROS, in prostate cancer growth and survival : 066
Multimodal hyperbranched polymers targeting prostate specific membrane antigen (PSMA) for imaging of prostate cancer : 067
PI3K/Akt signalling regulates leucine transport in prostate cancer : 068
Elucidating the role of ZEB1 in metastatic castration resistant prostate cancer : 070
Visualization of next generation sequencing data : 074
Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist : 075
Characterisation of novel primary tumour derived epithelial prostate cancer cell lines : 076
A multiple nucleotide length polymorphism (MNLP) mediates androgen regulation of IRX4 in prostate cancer : 077
Moduiation of protease expression in prostate cancer cells after androgen deprivation : 078
Extracellular vesicles mediate paracrine signalling in androgen deprived prostate cancer : 079
Polysaccharopeptide enhanced the anti-cancer effect of gammatocotrienol through activation of AMPK : 080
Kallikrein-related peptidase 4 induces tumour microenvironment alterations that support tumour growth : 081
A 3D in vitro model reflecting the androgen deprivation state in prostate cancer bone metastasis : 082
MSH2 translocations are associated with clinically aggressive prostate cancer : 085
Combination of inhibitors of Hsp90 chaperone activity and inhibitors of Hsp induction for better targeting human prostate cancer : 091
The Hsp90 inhibitor, NVP-AUY922, produces anti-tumour activity through inhibition of fibronectin polymerization resulting in cytoskeletal reorganization : 095
High risk prostate cancer is associated with distinct transcriptional and lipid profiles in adipose tissue : 105
Investigating the role of neuroendocrine transdifferentiation in the progression to castration resistant prostate cancer : 108
Targeting neuropilin-1 to inhibit prostate cancer invasion and metastasis : 110
The mesenchymal-to-epithelial reverting transition is enriched in metastatic castration resistant prostate cancer and correlates with poor survival : 111
The essential role of ARF in prostate cancer microenvironment : 112
Resistance to abiraterone based castration is not predicted by ARv7 status in high-risk prostate cancer : 130
RNA-Seq of localized prostate cancer treated with “supercastration” therapy : 138
Mitochondrial genomic variation and prostate cancer in South African men : 141
A tale of tails - novel approach to immunotherapy of prostate cancer : 143
Australian prostate cancer bioresource, 2015 : 144
Insulin increases apoptotic resistance in prostate cancer cells, but are sensitised by metformin : 145
Leptin receptor antagonist, Allo-Aca, prevents migration, invasion and modifies lipogenesis pathways in prostate cells : 146
SUMOylation regulates stability and function of the receptor tyrosine kinase EphB4 : 149
Carica papaya leaf juice extracts have selective anti-proliferative responses in prostatic disease : 156
Evaluation of prostate oedema following permanent fiducial marker insertion in prostate cancer patients treated at the Townsville Cancer Centre (TCC) : 157
Investigation of deregulated lipid metabolism in advanced prostate cancer : 159
YB-1, a key regulator of androgen receptor signaling : 164
Tracking the origins and drivers of metastasis in prostate cancer : 167
Multianalyte assay for prostate cancer : 168
Determining the evolutionary origin of lymph node metastases in prostate cancer : 169
Factors affecting chromosomal translocations in prostate cancer : 180
A specific expression signature accurately predicts high grade prostate tumours in fat but not from adjacent benign tissues : 189
Targeting adaptive nutrient metabolism pathways as a therapy for prostate cancer : 191
Aggressive prostate cancer presentation within an African setting - are bacterial pathogens contributing to exasperated disease course? : 192
Rethinking stromal cells contribution in the drug screening approach of prostate cancer : 193
Minimally invasive surgery employing antagonistic, inflatable robot: evaluation of positioning accuracy and motion dynamics : 199
Patient-derived prostate cancer cells for piloting of drug sensitivity and resistance testing : 201
Genome Mapping - a new strategy to detect complex prostate cancer structural genomic rearrangements : 207
An Irish collaborative nursing approach to quality patient information: a national audit on patient written information post transrectal ultrasound guided biopsy : 020
Remote monitoring of advanced prostate cancer patients after androgen deprivation therapy using mobile health technology: opportunities for novel care models : 069
Couple therapy for men and their partners following prostate cancer diagnosis : 104
Evaluation of the Prostate Cancer Clinical Nurse Co-ordinator (PC-CNC) role in Australia : 106
ASTROID (Active Surveillance and other Treatment Options for Prostate Cancer): a decision aid : 107
Supportive care needs of prostate cancer patients living in urban and rural/regional areas in Australia : 109
Pre-surgical exercise programming to improve outcomes for men undergoing prostatectomy : 116
Instructions to ‘stop the urine flow’ prior to radical prostate surgery produces quantifiable bladder neck elevation when assessed clinically with transperineal ultrasound : 117
Doing qualitative research: an introduction : 120
The missing piece of the men's health puzzle: developing Australian's first prostate cancer and men's health centre : 126
Does partnership status affect the quality of life of men having robotic-assisted radical prostatectomy (RARP) for localised prostate cancer? : 133
‘Lets talk about sex’: a prospective audit of a Nurse Practitioner-led sexual health and erectile dysfunction (SHED) Clinic : 137
Surgical nursing is not just fast paced it can be supportive as well: The introduction of the Prostate Cancer Specialist Nurse at Greenslopes Private Hospital : 151
Proving a concept-delivering long term care to men living with prostate cancer : 166
Physical activity levels in men with bone metastatic prostate cancer and associations with physical and mental health outcomes : 171
Diverse function of the pelvic floor muscles in men: investigation of the speech-related activation of the striated urethral sphincter and puborectalis muscles : 172
Interpretation of transperineal ultrasound imaging of pelvic floor muscle contraction in men : 176
Maintaining bone health in men with prostate cancer : 184
Musculoskeletal comparison of patients with localised versus metastatic prostate cancer : 187
PROSTMATE: web-based technology to support men with prostate cancer : 188
Clinical usefulness of the supportive care needs survey for men with advanced prostate cancer : 190
Multidisciplinary team meetings, do they make a difference? A systematic review of the impact of multidisciplinary team meetings on patient assessment, management and outcomes : 202